ProCE Banner Activity

ELOQUENT-2: Addition of Elotuzumab to Len/Dex Extends PFS in Relapsed/Refractory Myeloma

Slideset Download
Conference Coverage
Results from a randomized phase III trial investigating the addition of the mAB elotuzumab to lenalidomide and dexamethasone in patients with relapsed/refractory MM.

Released: June 05, 2015

Expiration: June 03, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation